Clinical trials: Advanced Solid Tumors (Phase 1)
Gastrointestinal Tumors, Solid Tumors
A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open-label, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of Lutetium [177Lu] BL-ARC001 in patients with locally…
- Trial name
- NCT07232407
- Testing
- Lutetium [177Lu] BL-ARC001
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A19 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
- Trial name
- NCT06990464
- Testing
- SIBP-A19
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Shanghai Institute Of Biological Products
Advanced Solid Tumors, Recurrent or Progressive Glioblastoma
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recurrent or progressive GBM (Cohort C) (collectively called 'indication…
- Conditions
- Advanced Solid Tumors, Recurrent or Progressive Glioblastoma, Relapse or Refractory Myeloid Malignancies
- Trial name
- TelOscope (NCT07779798)
- Testing
- CBX-663
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Crossbow Therapeutics, Inc.
Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β) trap in subjects with locally advanced or…
- Trial name
- NCT04958434
- Testing
- TST005
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Cancer, Melanoma
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts.
- Conditions
- Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer
- Trial name
- NCT04205227
- Testing
- ENB003, Pembrolizumab
- Where
- 5 sites in United States, Australia
- Volunteers
- 137 people
- Sponsor
- ENB Therapeutics, Inc
Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer)
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are…
- Conditions
- Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
- Trial name
- NCT05873686
- Testing
- NXP900
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Nuvectis Pharma, Inc.
Gastrointestinal Tumor, Solid Tumor
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expanded-enrollment, nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M09D1 for…
- Trial name
- NCT06954077
- Testing
- BL-M09D1
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Malignancies
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.
- Trial name
- NCT01112397
- Testing
- AZD1480
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Neoplasm
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
A clinical study evaluates the safety, tolerability, and pharmacokinetics of ridaforolimus (MK-8669) in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT00694083
- Testing
- Ridaforolimus
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- SCOUT (NCT02637687)
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 45 sites in United States, Australia and 19 more
- Volunteers
- 154 people
- Sponsor
- Bayer
Solid Tumor, Melanoma
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Melanoma, HNSCC, Sarcoma
- Trial name
- NCT04370587
- Testing
- T3011, T3011 + pembrolizumab
- Where
- 9 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- ImmVira Pharma Co. Ltd
Advanced or Metastatic Solid Tumors
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults…
- Trial name
- NCT05382325
- Testing
- MK-1484, Pembrolizumab
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors, Metastatic Melanoma
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP)…
- Trial name
- NCT03864042
- Testing
- losartan, dextromethorphan, caffeine
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 56 people
- Sponsor
- Pfizer
Solid Tumors
A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of E7050 when administered orally twice daily to patients with advanced…
- Trial name
- NCT00921869
- Testing
- E7050
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Eisai Co., Ltd.
Solid Tumor, Adult
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single…
- Trial name
- IO-001 (NCT03873883)
- Testing
- EOS100850, Pembrolizumab, Chemotherapy
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 119 people
- Sponsor
- iTeos Therapeutics
Malignant Solid Tumour
ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers
The purpose of the study is to investigate the safety and the recommended dose for later use of an oncolytic adenovirus CGTG-102 in combination with low-dose oral cyclophosphamide in the treatment of advanced cancers.
- Trial name
- NCT01598129
- Testing
- ONCOS-102
- Where
- Finland
- Volunteers
- 12 people
- Sponsor
- Targovax Oy
Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment.
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Trial name
- NCT00585845
- Testing
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Where
- 4 sites in United States, Israel
- Volunteers
- 17 people
- Sponsor
- Anza Therapeutics, Inc.
Advanced or Metastatic Solid Tumors
Phase I of XKH002 Injection in Patients
This is a Phase 1, first-in-human (FIH), open-label, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of XKH002 in patients with advanced or…
- Trial name
- NCT06196762
- Testing
- XKH002 Injection
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Advanced Solid Tumors, Non Small Cell Lung Cancer
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere).
- Trial name
- NCT00712504
- Testing
- sunitinib, docetaxel
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Bladder Cancer
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body.
- Conditions
- Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06580938
- Testing
- PF-07921585, Sasanlimab
- Where
- 9 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.